SBL
AXDX

Sargent Bickham Lagudis’s Accelerate Diagnostics AXDX Stock Holding History

Sargent Bickham Lagudis’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-152
Closed -$12K – 934
2020
Q4 		$12K Hold
152
– – ﹤0.01% 628
2020
Q3 		$16K Hold
152
– – ﹤0.01% 533
2020
Q2 		$23K Hold
152
– – ﹤0.01% 463
2020
Q1 		$13K Hold
152
– – ﹤0.01% 521
2019
Q4 		$26K Hold
152
– – ﹤0.01% 485
2019
Q3 		$28K Buy
+152
New +$29.4K ﹤0.01% 423

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Sargent Bickham Lagudis's AXDX Position: Q1 2021 in Review

Sargent Bickham Lagudis sold out of Accelerate Diagnostics (AXDX) in Q1 2021, closing a stake of 152 shares — an estimated $12K sold.

Sargent Bickham Lagudis first reported a position in AXDX in Q3 2019 and held it in 6 quarters. The position peaked at $28K in Q3 2019. 99 funds tracked by Wall St. Rank hold AXDX as of Q1 2021.

  • Sargent Bickham Lagudis reported no remaining Accelerate Diagnostics position as of Q1 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 152 Accelerate Diagnostics shares in Q1 2021, an estimated $12K.
  • Sargent Bickham Lagudis first reported a position in Accelerate Diagnostics in Q3 2019 and held it in 6 quarters.
  • Sargent Bickham Lagudis's Accelerate Diagnostics position peaked at $28K in Q3 2019.
  • 99 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2021, filed 24 May 2021.